Polaryx Therapeutics, Inc. PLYX Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

Zevra Therapeutics, Inc.ZVRA

-$2.05M-618%

Eton Pharmaceuticals, Inc.ETON

-$1.75M+41.0%

PVL

Palvella TherapeuticsPVLA

$357K+144%

PTC TherapeuticsPTCT

-$1.18M-107%

BioCryst PharmaceuticalsBCRX

-$3.53M-2,776%

Ironwood PharmaceuticalsIRWD

-$6M-1,573%

Operating income-$2.0M+61.2%

Net income-$2.5M+49.6%

EPS (diluted)-$0.05+54.5%

Cash & equivalents$3.1M+1,132%

Total equity$2.5M-41.5%

Total assets$3.5M—

Operating cash flow-$2.1M-191%

Market cap$132.59M-86.9%

Return on equity-1,209.8%—

Current ratio3.5×—

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Polaryx Therapeutics, Inc. ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Polaryx Therapeutics, Inc. 's increase (decrease) in prepaid expense and other assets?: Polaryx Therapeutics, Inc. (PLYX) reported increase (decrease) in prepaid expense and other assets of $395K in Q1 2026.
What does increase (decrease) in prepaid expense and other assets mean?: This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.